UNSPSC 51372040: Nalbuphine hydrochloride

This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H27NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZU4275277R, chemically known as 17-(cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol hydrochloride but more generally known as nalbuphine hydrochloride, which bears US NIH Compound Identifier 5360733. European Medicines Agency schedules Nalbuphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14626MIG.

UNSPSC 51372040 Nalbuphine hydrochloride is a Commodity code covering specific pharmaceutical products procured by state and local health agencies, typically as part of broader opioid-response or pain-management initiatives. State and local governments buying under this code seek nalbuphine and related opioid antagonists and medications for emergency response, community health programs, and pharmacy benefit management across municipal health departments, county public health systems, and state health and human services commissions. Recent solicitations show nalbuphine procured alongside naloxone and drug deactivation systems for emergency medical response, as well as through multistate cooperative purchasing arrangements for generic pharmaceuticals distributed via established wholesale channels. Issuing bodies include individual county health systems, state health and human services agencies, and multistate cooperative purchasing alliances representing multiple participating jurisdictions.

Recent activity centers on Florida and Minnesota through multistate cooperative structures. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 exploring vendor capability for direct-to-manufacturer prescription programs that could encompass nalbuphine and related drugs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors under MMCAP must maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, comply with cGMP and Drug Supply Chain Security Act requirements, and accept a 3 percent administrative fee on all purchases.